Eloralintide looks good for obesity

Treatment with the novel selective amylin receptor agonist eloralintide results in substantial, dose-dependent reductions in bodyweight in adults with obesity, according to a phase II trial.

A total of 263 adults (mean age 49 years, 78 percent female, 78 percent White) with a BMI of at least 30 kg/m² or a BMI of at least 27 kg/m² with at least one weight-related comorbidity participated in the trial. None of the participants had type 2 diabetes. The mean bodyweight was 109.1 kg, while the mean BMI was 39.1 kg/m².

The participants were randomly assigned to receive eloralintide at 1 mg (n=28), 3 mg (n=24), 6 mg (n=28), or 9 mg (n=54), or dose escalations of 6–9 mg (n=24) or 3–9 mg (n=52) or placebo (n=53), administered subcutaneously once weekly for 48 weeks. The primary endpoint was percent change in bodyweight from baseline after 48 weeks of treatment.

At week 48, the mean percent change in bodyweight from baseline was –9 percent (95 percent confidence interval [CI], –12.6 to –6.3) with 1-mg eloralintide, –12 percent (95 percent CI, –14.9 to –9.8) with 3 mg, –18 percent (95 percent CI, –20.7 to –14.5) with 6 mg, –20 percent (95 percent CI, –22.7 to –17.5) with 9 mg, –20 percent (95 percent CI, –22.7 to –17) with 6–9 mg, and –16 percent (95 percent CI, –18.6 to –14.1) with 3–9 mg vs only –0.4 percent (95 percent CI, –2.2 to 1.4) with placebo.

In terms of safety, the most common adverse events with eloralintide were nausea and fatigue.

The findings point to eloralintide's potential use for obesity treatment.